ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,848Medicare Part D Prescriptions Filled, Including Refills

Rank: 312 out of 1844

$517K Total Retail Price of All Prescriptions

Rank: 329 out of 1844

336 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
55% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 336 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

20% of this provider’s 336 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 7,113 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
LEVOTHYROXINE SODIUM 547 440 1 1
HYDROCODONE-ACETAMINOPHEN 323 247 S3 2 2
FUROSEMIDE 272 244 3 7
SIMVASTATIN 256 219 4 3
LISINOPRIL 240 188 5 4
METOPROLOL TARTRATE 191 160 6 11
AMLODIPINE BESYLATE 182 179 7 6
OMEPRAZOLE 159 130 8 5
WARFARIN SODIUM 129 104 9 13
ATORVASTATIN CALCIUM 120 111 10 12
GABAPENTIN 118 92 11 15
HYDROCHLOROTHIAZIDE 113 84 12 9
TAMSULOSIN HCL 112 93 13 27
MIRTAZAPINE 110 94 14 49
POTASSIUM CHLORIDE 108 100 15 16
DOXYCYCLINE HYCLATE 95 76 16 90
CITALOPRAM HBR 95 42 16 19
FLUTICASONE PROPIONATE 94 77 18 50
METOPROLOL SUCCINATE 92 78 19 14
ALENDRONATE SODIUM 91 91 20 25
FLUOXETINE HCL 91 76 20 41
LANTUS 89 82 22 42
METFORMIN HCL 86 68 23 8
CYMBALTA 81 67 24 36
SERTRALINE HCL 79 47 25 21
ALLOPURINOL 78 67 26 29
AZITHROMYCIN 77 66 27 37
ZOLPIDEM TARTRATE 74 43 28 23
CRESTOR 73 43 29 30
CEPHALEXIN 72 64 30 56
OXYBUTYNIN CHLORIDE ER 71 47 31 126
ATENOLOL 71 71 31 17
NAMENDA 71 71 31 33
NOVOLIN 70-30 70 70 34 248
DONEPEZIL HCL 66 66 35 26
LOSARTAN-HYDROCHLOROTHIAZIDE 65 59 36 47
FENTANYL 64 64 S2 37 66
DIVALPROEX SODIUM 63 41 38 74
VERAPAMIL ER 63 63 38 98
LISINOPRIL-HYDROCHLOROTHIAZIDE 62 49 40 20
LOSARTAN POTASSIUM 62 62 40 24
GLIMEPIRIDE 62 60 40 35
CARVEDILOL 61 53 43 22
SPIRONOLACTONE 59 50 44 60
PREDNISONE 54 45 45 40
TRAZODONE HCL 50 48 46 43
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 23, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.